Cirtuvivint (SM08502) is a potent oral active inhibitor optimized for mRNA splicing and is an inhibitor of CDC-like kinase (CLK) and DYRK (bi-specific tyrosine kinase) for Wnt pathway inhibition. Cirtuvivint inhibits phosphorylation of serine - and arginine-rich splicing factors (SRSF) and disrupts spliceosome activity. Cirtuvivint can be used to study solid tumors.

 

Brand: BCM

 

Target: CDK

 

Signaling Pathways: Cell Cycle/Checkpoint

 

In Vitro: Inhibiting serine and arginine-rich splicing factor (SRSF) phosphorylation and disrupting spliceosome activity, Cirtuvivint (SM08502) is associated with the inhibition of Wnt pathway-related gene and protein expression. Cirtuvivint induces the generation of splicing variants of Wnt pathway genes, suggesting that its mechanism for inhibiting gene expression includes effects on alternative splicing.

 

Solubility: Soluble in DMSO. Insoluble in Water; Insoluble in Ethanol.

 

Isomeric SMILES: CN1CCN(CC1)C2=NC=CC(=C2)C(=O)NC3=NC=C4C=CC(=CC4=C3)C5=CN(N=C5)C  

 

InChIKey: BQWWOBKMDWACGC-UHFFFAOYSA-N  

 

InChI: InChI=1S/C24H25N7O/c1-29-7-9-31(10-8-29)23-13-18(5-6-25-23)24(32)28-22-12-20-11-17(3-4-19(20)14-26-22)21-15-27-30(2)16-21/h3-6,11-16H,7-10H2,1-2H3,(H,26,28,32)

 

Attribute
[Chem Name]	2-(4-methylpiperazin-1-yl)-N-[6-(1-methylpyrazol-4-yl)isoquinolin-3-yl]pyridine-4-carboxamide
[Synonym]	Cirtuvivint; SM08502
[CAS No.]	2143917-62-6
[Formula]	C24H25N7O
[Molecular]	427.5
[Form]	Solid powder
[Storage]	Sealed in dry. Stored at -20°C.

Goods Tag